1. A live attenuated influenza B virus vaccine expressing RBD elicits protective immunity against SARS-CoV-2 in mice
- Author
-
Zhenfei Wang, Weiyang Sun, Dongxu Li, Yue Sun, Menghan Zhu, Wenqi Wang, Yiming Zhang, Entao Li, Feihu Yan, Tiecheng Wang, Na Feng, Songtao Yang, Xianzhu Xia, and Yuwei Gao
- Subjects
SARS-CoV-2 ,Influenza virus-vector vaccine ,Spike RBD ,Intranasal vaccination ,Mice ,Microbiology ,QR1-502 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a significant threat to human health globally. It is crucial to develop a vaccine to reduce the effect of the virus on public health, economy, and society and regulate the transmission of SARS-CoV-2. Influenza B virus (IBV) can be used as a vector that does not rely on the current circulating influenza A strains. In this study, we constructed an IBV-based vector vaccine by inserting a receptor-binding domain (RBD) into a non-structural protein 1 (NS1)-truncated gene (rIBV-NS110-RBD). Subsequently, we assessed its safety, immunogenicity, and protective efficacy against SARS-CoV-2 in mice, and observed that it was safe in a mouse model. Intranasal administration of a recombinant rIBV-NS110-RBD vaccine induced high levels of SARS-CoV-2-specific IgA and IgG antibodies and T cell-mediated immunity in mice. Administering two doses of the intranasal rIBV-NS110-RBD vaccine significantly reduced the viral load and lung damage in mice. This novel IBV-based vaccine offers a novel approach for controlling the SARS-CoV-2 pandemic.
- Published
- 2024
- Full Text
- View/download PDF